Jazz reprices $2.7B term loan; margin cut 75 bps to 2.25%+SOFR

Jazz Pharmaceuticals plc

Entered Amendment No. 2 to Credit Agreement; Tranche B-2 Dollar Term Loans replace Tranche B-1 at same $2,707,000,000 outstanding.
Interest margin reduced 75 basis points: new rates are 2.25% (Term SOFR) and 1.25% (prime) vs prior margins.
Maturity unchanged at May 5, 2028; quarterly amortization of 0.2863% of initial principal; SOFR floor of 0.50% remains.
Proceeds from new $289.6M additional borrowing used to repay non-converted Tranche B-1 loans; structure includes converting and non-converting lenders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.